查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844199

神经血管介入器材市场（按产品类型、适应症、最终用户和手术类型）—2025 年至 2032 年全球预测

Neurovascular Intervention Devices Market by Product Type, Indication, End User, Procedure Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，神经血管介入器材市场将成长至 71.4 亿美元，复合年增长率为 6.69%。

主要市场统计数据
基准年2024年 42.5亿美元
预计2025年 45.3亿美元
预测年份：2032年 71.4亿美元
复合年增长率（%） 6.69%

对近期神经血管设备创新、临床应用的驱动因素以及相关人员决策的策略考量进行清晰且引人入胜的定位

在设备工程、影像学和急性护理途径融合发展的推动下，神经血管介入器材领域正在快速发展。过去几年，临床医生和器械开发者已从渐进式改进转向平台级创新，这些创新正在彻底改变复杂脑血管疾病的诊断、治疗和管理方式。这种转变使得相关人员不仅需要了解产品层面的差异化因素，还需要了解手术流程、报销动态和照护环境偏好如何相互作用，进而影响设备的采用和疗效。

本执行摘要概述了神经血管领域及其相关领域的製造商、临床领导者和投资者面临的跨领域趋势和策略要务。本书将诸如血流导流材料和血栓除去装置输送能力的提升等技术进步，与不断发展的手术方法和付款人考量因素相结合。本书旨在透过重点介绍临床应用的驱动因素以及跨产品类型和适应症的竞争格局，为决策者提供清晰、可行的观点，以支持其优先考虑研发、上市和伙伴关係策略。

在以下章节中，分析着重于实际意义，平衡技术细节和商业性背景，以便将见解快速转化为产业计画和资源分配。

材料科学、成像整合和不断发展的护理服务模式的突破如何重塑神经血管护理中的设备采用和临床路径

神经血管器械领域正在经历一场变革性的转变，其影响已超越器械层面的改进，涵盖操作模式和医疗服务模式。材料科学的突破和精妙的设计正在提升器械的功效和安全性，使临床医生能够处理以往无法治疗的解剖结构和复杂的病变形态。同时，增强的影像整合和导航系统正在缩短手术时间并提高器械部署的准确性。

随着手术成功率和操作人员熟练程度的提高，新的治疗途径不断涌现，包括在门诊手术环境中的推广应用，以及简化分诊和治疗的多学科卒中网络的建立。强调基于价值的照护和结果报告，进一步强化了这种系统性转变，从而奖励人们采用能够显着减少併发症、再入院率和长期残疾的设备和手术方法。因此，那些将产品开发与可衡量的临床结果和简化的工作流程相结合的公司将占据更有利的地位。

最后，器械製造商和临床中心之间的合作模式正在不断发展，以加速真实世界证据的生成和器械的迭代改进。整合上市后监测、註册登记和付款人参与的策略伙伴关係正成为商业化策略的重要组成部分，重塑创新从监管核准到常规临床实践的进程。

评估新关税政策对神经血管设备相关人员的供应链、采购决策和商业化策略的实际影响

2025年，美国将对某些医疗设备组件和成品征收关税，这为神经血管器械相关人员的采购和供应链带来了新的复杂性。拥有全球製造地的製造商被迫重新评估筹资策略和成本结构，以缓解利润下滑并保持价格竞争力。同时，医疗系统和集团采购组织内的采购团队正在权衡短期成本增长与长期临床价值之间的利弊，尤其关注那些能够显着缩短手术时间、降低併发症发生率或减少后续护理需求的器械。

立即采取的应对措施包括重新评估供应商合同，强调近岸外包和区域製造伙伴关係，并在合约弹性和付款方动态允许的情况下选择性地重新定价产品。在某些情况下，开发商正在加快对设计简化和组件整合的投资，以减少受关税衝击的投入。同时，临床医生和医院管理人员专注于保持诊疗的连续性，并确保获得一流的医疗设备。因此，策略性地传达健康经济效益和比较临床结果以抵消采购压力变得更加重要。

随着关税相关成本压力持续存在，那些能够证明总护理成本效益、确保供应链韧性、并根据不断变化的采购框架调整商业策略的机构将占据优势。透明的成本效益证据和灵活的分销协议对于在贸易条件变化的情况下保持市场进入至关重要。

综合细分洞察揭示了产品类型、临床指征、医疗保健环境和程序类型如何推动采用动态和商业性优先级

市场区隔框架透过整合产品、适应症、最终使用者和程序观点提供具体见解。根据产品类型，栓塞剂、流量转向器、微导管、神经血管线圈、支架和血栓切除装置等设备类别各自表现出不同的临床和商业性动态。在栓塞剂中，液体和颗粒栓塞剂之间的差异会影响程序、储存和处理注意事项以及临床使用案例。流量转向器在管道栓塞装置和超越流量转向器等设备中呈现出差异化的价值提案，输送能力、径向力和内皮化特征的差异会影响临床医生的偏好。微导管涂层，无论是亲水性或聚合物基，都会改变操作员所依赖的触觉和导航特性。支架平台、球囊展开和自膨胀在病灶准备和展开工作流程方面有所不同，血栓切除策略分为抽吸器和支架回收器。

从适应症角度来看，动脉瘤治疗、动静脉畸形治疗和急性缺血性中风治疗对设备性能、库存管理和手术团队组成提出了不同的要求。最终使用者按门诊、诊所和医院环境进行细分，进一步改变了部署时间表和采购行为。门诊中心通常优先考虑精简、高通量的解决方案，而医院则重视多功能性和全面的库存，以支援复杂的病例。最后，栓塞、血流改道和血栓切除术等手术类型的细分揭示了手术量、操作人员专业知识和病例复杂性如何相互作用，从而决定设备组合和耗材的使用。

总的来说，这些细分强调了根据每个临床和操作环境的细微需求客製化产品设计、培训计划和商业性通讯的重要性。

比较区​​域动态，揭示法规环境、付款人结构和临床网路如何推动差异化采用和商业化路径

神经血管介入治疗的区域动态反映了法律规范、卫生系统架构和临床实践模式的差异。在美洲，先进的卒中系统和强大的三级医疗网络促进了血管内介入治疗方案的快速应用，重点是整合院前分诊和院间转运通讯协定，以最大限度地实现及时干预。该地区通常为新医疗设备的早期应用提供了良好的环境，前提是这些医疗器材有强有力的临床证据和经济可行性支持，并且支付方在製定承保决策时越来越多地审查比较结果。

在欧洲、中东和非洲，某些市场的监管环境趋于协调，而其他市场的准入和报销政策则呈现多样性。临床医生网路和卓越中心 (COE) 模式推动了主要都市区的采用，而更广泛的人口采用则取决于当地采购惯例和报销政策的协调。部分欧洲、中东和非洲市场的资本预算限制正在推动基于价值的采购和长期医疗成本分摊的讨论，为能够显着减轻整体护理负担的医疗设备创造了投资机会。

亚太地区正见证大批量生产设施的快速应用，同时国内器械开发生态系统也在不断发展。该地区的医疗保健系统正在投资卒中基础设施和先进的介入神经放射学培训，以支援现有和新型器械类别的扩展。然而，分散的监管途径和多样化的支付方安排使得打入市场策略需要细緻入微，包括与本地伙伴关係建立合作伙伴关係以及产生针对特定地区的临床证据。在所有地区，供应链的韧性、监管准备度以及针对当地实践模式的客製化证据都是成功进入市场的关键因素。

透过临床证据、製造敏捷性以及与医疗保健系统优先事项的策略一致性来决定市场领导地位的动态和协作动态

神经血管介入领域的竞争态势由众多成熟的器材创新者、新兴的专业公司以及垂直整合的医疗科技公司共同塑造。规模较大的公司通常会大力投资于器械的迭代改进、强大的临床试验项目以及广泛的培训计划，以缩短操作人员的学习曲线并加速机构的采用。同时，规模较小、更敏捷的公司则经常推出差异化的材料和给药机制，尤其是在细分的解剖结构和手术流程中，这些领域的渐进式改进可以带来显着的临床效益，挑战现有公司并促进品类扩张。

设备开发商与临床卓越中心之间的伙伴关係是产生真实世界证据并根据操作回馈优化设备迭代的常见策略方法。此类合作模式透过累积本地专业知识并产生支付方参与所需的结果数据，有助于加速临床应用。此外，那些将商业策略与医疗系统优先事项（例如缩短住院时间、降低併发症发生率以及实现当日手术）相结合的公司更有可能获得处方集的收录并获得有利的采购条款。

强大的智慧财产权、扩充性的生产能力和多元化的供应链仍然是至关重要的竞争优势。持续投资于上市后监测、教育计画和全面临床支援的公司，能够更好地维持市场份额，并拓展至邻近的适应症和地区。实力雄厚的公司将技术力与在监管、报销和临床应用管道的营运能力相结合。

可行的策略和营运建议，用于协调产品设计、证据生成和商业性执行，以确保永续的采用和价值

产业领导者应采取协调产品开发、证据产生和商业性执行的策略，以加速应用并维护其市场地位。优先考虑能够优化交付能力和手术效率的设计方案，这将引起那些专注于缩短手术时间和提高安全性的临床医生的共鸣。同时，投资于可靠的真实世界证据项目和卫生经济学分析对于说服采购委员会和付款人相信设备选择将显着降低医疗保健总成本至关重要。

在营运方面，企业应透过多元化采购、探索区域製造伙伴关係以及在可行的情况下简化材料清单来提升供应链的韧性，以减轻贸易波动的影响。在商业性，根据最终用户细分客製化培训和支援模式，并针对门诊中心、诊所和医院采取差异化方法，可以在确保服务品质的同时加快技术应用。与领先的临床中心建立策略伙伴关係，共同开发最佳实践方案和案例库，缩短了学习曲线，并在更广泛的临床医生群体中建立了信任。

最后，领导团队必须在定价和合约模式上保持弹性，以适应不同的报销环境和采购流程。当结果资料支援基于价值的合约、风险分担安排和捆绑支付模式时，应考虑此类结构。将临床、营运和商业优先事项整合到一个连贯的计划中，使组织能够将创新转化为永续的临床和财务价值。

一种透明、多方法的调查方法，结合专家访谈、文献综合和情境测试，提供可靠、可行的见解

本分析所依据的调查方法整合了多种定性和定量分析方法，以确保研究的严谨性和有效性。主要资讯包括与临床专家、采购主管和行业高管进行结构化访谈，以深入了解流程、应用驱动因素和采购决策标准。这些访谈与同行评审的临床文献、监管文件和会议记录相结合，以检验性能声明并确定新兴的临床共识。

补充性二手研究检视了器械设计趋势、製造考量和供应链动态，并着眼于贸易政策变化和区域监管发展。该调查方法还结合了对报销和卫生经济学文献的评估，以建构采用奖励和付款人观点。资料整合强调跨来源的交叉检验，资讯来源结果和专家意见，并提供关键结论可信度的透明度。

在适当的情况下，我们会运用情境分析来探讨政策变化、供应链中断以及不同医疗机构采用率差异的影响。在整个过程中，该方法优先考虑切实可行的洞察，将技术设备属性与对临床医生、医院管理人员和投资者至关重要的营运和商业成果联繫起来。

将设备创新、证据策略和营运弹性连结起来的结论性综合是永续影响和竞争优势的关键。

摘要，神经血管介入领域正从渐进式改善到变革性创新转型，这些创新正在再形成临床路径、采购行为和竞争动态。器械设计和手术技术的进步正在拓展治疗可能性并改善疗效，但成功的商业化越来越需要整合策略。 2025年的关税格局强调了敏捷筹资策略和更清晰地展示总医疗成本效益的必要性，以维持市场准入和临床医生的采用。

针对产品细微差别、适应症要求、最终用户偏好和流程环境，量身定制的细分市场方法对于确定投资优先事项和提案引人注目的价值主张至关重要。差异化的地域策略同样重要，因为监管、报销和医疗保健交付框架将对采用的时间和规模产生重大影响。将卓越技术与严格的循证计划、适应性强的商业模式和富有韧性的业务运营相结合的公司将最有可能占据主导。

最终，从创新到标准化治疗的路径取决于临床、商业和营运领域的全面执行。积极主动协调这些要素的相关人员将获得最大价值，并为改善神经血管治疗的患者预后做出有意义的贡献。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 使用血流改道装置治疗复杂颅内动脉瘤可提高长期阻塞率
  • 可生物降解栓塞材料的进展降低慢性发炎风险并促进血管重塑
  • 即时机器人辅助神经血管导航系统的整合提高了手术的精确度和安全性
  • 开发下一代薄壁支架，以改善血管相容性并减少血栓形成
  • 实施人工智慧驱动的影像分析以优化血管内手术计划
  • 对于具有改进扭矩控制的微导管的需求日益增长，以便有效地导航曲折的脑血管。
  • 扩展的混合手术室套件结合了 CT血管造影术和萤光透视技术，以简化神经介入治疗
  • 微创液体栓塞剂的发展，可实现低风险的标靶血管闭塞

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章神经血管介入器材市场（依产品类型）

  • 栓塞剂
    • 液体栓子
    • 颗粒栓塞
  • 流量转向器
    • 管道栓塞装置
    • 超越流量转向器
  • 微导管
    • 亲水涂层
    • 聚合物涂层
  • 神经血管线圈
    • 可拆卸线圈
    • 可推线圈
  • 支架
    • 气球安装
    • 自膨胀
  • 血栓除去装置
    • 吸力装置
    • 支架取栓器

第九章神经血管介入器材市场（按适应症）

  • 动脉瘤
  • 动静脉畸形
  • 中风

第 10 章神经血管介入器材市场（依最终用户）

  • 门诊中心
  • 诊所
  • 医院

第 11 章神经血管介入器械市场（依手术类型）

  • 栓塞治疗
  • 流量转换
  • 血栓切除术

第12章神经血管介入器材市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章神经血管介入器材市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章神经血管介入器材市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Stryker Corporation
    • Medtronic plc
    • Johnson & Johnson
    • Penumbra, Inc.
    • Boston Scientific Corporation
    • Terumo Corporation
    • Becton, Dickinson and Company
    • MicroPort Scientific Corporation
    • MicroVention, Inc.
    • Kaneka Corporation
Product Code: MRR-ED54C46E8FA1

The Neurovascular Intervention Devices Market is projected to grow by USD 7.14 billion at a CAGR of 6.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.25 billion
Estimated Year [2025] USD 4.53 billion
Forecast Year [2032] USD 7.14 billion
CAGR (%) 6.69%

A clear and engaging orientation to recent neurovascular device innovations, clinical adoption drivers, and strategic considerations shaping stakeholder decisions

The landscape of neurovascular intervention devices is evolving rapidly, driven by convergent advances in device engineering, imaging, and acute care pathways. Over the last several years clinicians and device developers have moved from incremental improvements toward platform-level innovations that change how complex cerebrovascular diseases are diagnosed, treated, and managed. These shifts have heightened the imperative for stakeholders to understand not only product-level differentiators but also how procedural workflows, reimbursement dynamics, and care setting preferences interact to shape adoption and outcomes.

This executive summary synthesizes cross-cutting trends and strategic imperatives for manufacturers, clinical leaders, and investors who operate in or adjacent to the neurovascular domain. It situates technology progress-such as enhancements in flow diversion materials and thrombectomy device deliverability-alongside evolving procedural approaches and payer considerations. By clarifying the drivers of clinical adoption and the competitive tensions across product categories and indications, the narrative aims to equip decision-makers with a clear, actionable perspective that supports prioritization of R&D, go-to-market investments, and partnership strategies.

Throughout the following sections, the analysis maintains an emphasis on practical implications, balancing technical detail with commercial context to facilitate rapid translation of insight into operational planning and resource allocation.

How material science breakthroughs, imaging integration, and evolving care delivery models are reshaping device adoption and clinical pathways in neurovascular care

The neurovascular device landscape is undergoing transformative shifts that extend beyond device-level improvements to encompass procedural paradigms and care delivery models. Material science breakthroughs and refined designs have increased device efficacy and safety profiles, enabling clinicians to tackle previously untreatable anatomies and complex lesion morphologies. Simultaneously, enhanced imaging integration and navigation systems have reduced procedural times and improved the precision of device deployment, which in turn has broadened the pool of eligible patients and increased clinician confidence in advanced interventions.

As procedural success rates and operator familiarity grow, new pathways for care are emerging, including expanded utilization in ambulatory surgical settings and the creation of multidisciplinary stroke networks that streamline triage and treatment. These systemic shifts are reinforced by an emphasis on value-based care and outcomes reporting, which incentivize devices and procedural approaches that demonstrably reduce complications, rehospitalizations, and long-term disability. Consequently, companies that align product development with measurable clinical outcomes and streamlined workflows will be better positioned to gain traction.

Finally, collaboration models between device manufacturers and clinical centers are evolving to accelerate real-world evidence generation and iterative device refinement. Strategic partnerships that integrate post-market surveillance, registries, and payer engagement are becoming essential components of commercialization strategies, reshaping how innovations migrate from regulatory approval to routine clinical practice.

Assessing the practical repercussions of new tariff policies on supply chains, procurement decisions, and commercialization strategies across neurovascular device stakeholders

The introduction of tariffs in 2025 for certain medical device components and finished goods has introduced an additional layer of procurement and supply chain complexity for neurovascular device stakeholders. Manufacturers with global manufacturing footprints have been prompted to reassess sourcing strategies and cost structures to mitigate margin erosion and maintain price competitiveness. In turn, procurement teams within health systems and group purchasing organizations are weighing the trade-offs between short-term cost increases and long-term clinical value, particularly for devices that deliver demonstrable reductions in procedure time, complication rates, or subsequent care requirements.

Immediate responses have included a re-evaluation of supplier contracts, increased emphasis on nearshoring or regional manufacturing partnerships, and selective repricing of products where contractual flexibility and payer dynamics permit. In some cases, developers have accelerated investments in design simplification and component consolidation to reduce exposure to tariffed inputs. Meanwhile, clinicians and hospital administrators are focused on preserving procedural continuity and access to best-in-class devices; therefore, strategic communication of health-economic benefits and comparative clinical outcomes has become more critical to offset procurement pressures.

Looking ahead, sustained tariff-related cost pressures will favor organizations that can demonstrate total cost of care benefits, secure resilient supply chains, and adapt commercial strategies to evolving procurement frameworks. Transparent cost-effectiveness evidence and flexible distribution agreements will be pivotal in maintaining market access under shifting trade conditions.

Integrated segmentation insights that reveal how product types, clinical indications, care settings, and procedure types jointly determine adoption dynamics and commercial priorities

The market segmentation framework yields specific insights when product, indication, end user, and procedure perspectives are integrated. Based on product type, device categories such as embolic agents, flow diverters, microcatheters, neurovascular coils, stents, and thrombectomy devices each present distinct clinical and commercial dynamics. Within embolic agents, the distinctions between liquid embolics and particulate embolics influence procedural technique, storage and handling considerations, and clinical use cases. Flow diverters show differentiated value propositions across devices such as the Pipeline Embolization Device and the Surpass Flow Diverter, where differences in deliverability, radial force, and endothelialization profiles affect clinician preference. Microcatheter coatings, whether hydrophilic or polymer-based, change the tactile and navigational characteristics that operators rely upon, while coil technologies that are detachable versus pushable define different trade-offs in deployment control and repositionability. Stent platforms that are balloon-mounted versus self-expanding present distinct lesion preparation and deployment workflows, and thrombectomy strategies split between aspiration devices and stent retrievers, each with specific procedural success patterns that inform institutional purchasing decisions.

When viewed through the lens of indication, aneurysm treatment pathways, arteriovenous malformation interventions, and acute ischemic stroke care place divergent demands on device performance, inventory management, and procedural team composition. End user segmentation-ambulatory centers, clinics, and hospitals-further modulates adoption timelines and procurement behaviors, with ambulatory centers often prioritizing streamlined, high-throughput solutions and hospitals emphasizing versatility and comprehensive inventory to support complex cases. Finally, procedure type segmentation across embolization, flow diversion, and thrombectomy highlights how procedural volume, operator expertise, and case complexity interact to determine device mix and consumable usage.

Taken together, these segmentation lenses underscore the importance of tailoring product design, training programs, and commercial messaging to the nuanced needs of each clinical and operational context, ensuring that innovations are positioned to overcome adoption barriers and deliver measurable clinical impact.

Comparative regional dynamics revealing how regulatory environments, payer structures, and clinical networks drive differentiated adoption and commercialization pathways

Regional dynamics in neurovascular interventions reflect differences in regulatory frameworks, health system architectures, and patterns of clinical practice. In the Americas, advanced stroke systems and robust tertiary care networks have facilitated rapid uptake of endovascular solutions, with a pronounced emphasis on integrating pre-hospital triage and inter-hospital transfer protocols to maximize timely intervention. This region often serves as an early adopter environment for novel devices when backed by strong clinical evidence and health-economic justification, and payers increasingly scrutinize comparative outcomes as part of coverage decisions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization in certain markets coexists with variable access and reimbursement policies in others. Clinician networks and center-of-excellence models drive adoption in major urban centers, while translation to broader populations depends on local procurement practices and reimbursement alignment. In some EMEA markets, constrained capital budgets emphasize value-based purchasing and long-term cost-of-care arguments, creating opportunities for devices that demonstrably reduce overall treatment burden.

Asia-Pacific exhibits rapid adoption in high-volume centers alongside growing domestic device development ecosystems. Health systems across the region are investing in stroke infrastructure and advanced neurointerventional training, which supports scaling of both established and newer device categories. However, fragmented regulatory pathways and diverse payer arrangements require nuanced market entry strategies, including local partnerships and region-specific clinical evidence generation. Across all regions, supply chain resilience, regulatory readiness, and evidence tailored to local practice patterns are decisive factors in successful market penetration.

Competitive and collaborative dynamics that determine market leadership through clinical evidence, manufacturing agility, and strategic alignment with health system priorities

Competitive dynamics in neurovascular interventions are shaped by a mix of established device innovators, emerging specialized firms, and vertically integrated healthcare technology companies. Leading organizations typically invest heavily in iterative device refinement, robust clinical trial programs, and broad training initiatives that reduce operator learning curves and accelerate institutional adoption. Meanwhile, smaller, agile firms frequently introduce differentiated materials or delivery mechanisms that challenge incumbents and catalyze category expansion, particularly in niche anatomies or procedural workflows where incremental improvements yield outsized clinical benefit.

Partnerships between device developers and clinical centers of excellence are a common strategic approach to generate real-world evidence and optimize device iterations based on procedural feedback. These collaborative models support faster clinical adoption by building local expertise and producing the outcome data required for payer engagement. Additionally, companies that align their commercial strategies with health system priorities-such as reducing length of stay, decreasing complication rates, or enabling same-day procedures-find it easier to secure formulary inclusion and favorable procurement terms.

Intellectual property strength, manufacturing scalability, and supply chain diversification remain decisive competitive levers. Organizations that demonstrate sustained investment in post-market surveillance, education programs, and integrated clinical support are better positioned to retain market share and expand into adjacent indications and geographies. The most resilient players combine technical excellence with operational fluency across regulatory, reimbursement, and clinical adoption channels.

Actionable strategic and operational recommendations for aligning product design, evidence generation, and commercial execution to secure sustainable adoption and value

Industry leaders should adopt a coordinated strategy that aligns product development, evidence generation, and commercial execution to accelerate adoption and defend market position. Prioritizing design choices that optimize deliverability and procedural efficiency will resonate with clinicians focused on reducing procedure time and improving safety outcomes. Concurrently, investing in robust real-world evidence programs and health-economic analyses will be critical to persuade procurement committees and payers that device selection yields measurable reductions in total cost of care.

Operationally, companies should pursue supply chain resilience by diversifying sourcing, exploring regional manufacturing partnerships, and simplifying bill-of-materials where feasible to mitigate exposure to trade fluctuations. Commercially, tailoring training and support models to end user segmentation-differentiating approaches for ambulatory centers, clinics, and hospitals-will help accelerate adoption while maintaining service quality. Strategic partnerships with leading clinical centers to develop best-practice protocols and case libraries will shorten learning curves and build trust among broader clinician cohorts.

Finally, leadership teams must maintain flexibility in pricing and contracting models to accommodate varied reimbursement environments and procurement processes. Value-based contracting, risk-sharing arrangements, and bundled payment models should be explored where outcomes data support such structures. By integrating clinical, operational, and commercial priorities into a single coherent plan, organizations can convert innovation into sustainable clinical and financial value.

A transparent and multi-method research approach that combines expert interviews, literature synthesis, and scenario testing to ensure robust, actionable insights

The research methodology underpinning this analysis integrates multiple qualitative and quantitative approaches to ensure rigour and relevance. Primary inputs include structured interviews with clinical experts, procurement leaders, and industry executives, which provide contextual understanding of procedural workflows, adoption drivers, and purchasing decision criteria. These conversations are triangulated with a review of peer-reviewed clinical literature, regulatory filings, and conference proceedings to validate performance claims and identify emerging clinical consensus.

Complementary secondary research examines device design trends, manufacturing considerations, and supply chain dynamics, with attention to changes in trade policy and regional regulatory developments. The methodology also incorporates an assessment of reimbursement and health-economic literature to frame adoption incentives and payer perspectives. Data synthesis emphasizes cross-validation across sources and a clear delineation between evidence-based findings and expert opinion, with transparency about the level of confidence for key conclusions.

Where appropriate, scenario analysis is used to explore the implications of policy shifts, supply chain disruptions, and differential adoption rates across care settings. Throughout, the approach prioritizes actionable insight, linking technical device characteristics to operational and commercial outcomes that matter to clinicians, hospital executives, and investors.

Concluding synthesis that connects device innovation, evidence strategy, and operational resilience as the keys to sustainable impact and competitive advantage

In summary, the neurovascular intervention space is transitioning from incremental refinements to transformative innovations that reshape clinical pathways, procurement behaviors, and competitive dynamics. Advances in device design and procedural technology are expanding treatment possibilities and improving outcomes, but successful commercialization increasingly requires integrated strategies that align clinical evidence, supply chain resilience, and payer engagement. The 2025 tariff landscape has amplified the need for nimble sourcing strategies and stronger articulation of total cost of care benefits to maintain market access and clinician adoption.

Segmentation-specific approaches-attuned to product nuances, indication requirements, end-user preferences, and procedural contexts-are essential to prioritize investments and craft persuasive value propositions. Regionally differentiated strategies are equally important, as regulatory, reimbursement, and care delivery frameworks materially influence adoption timing and scale. Companies that combine technical excellence with rigorous evidence programs, adaptable commercial models, and resilient operations will be best positioned to lead.

Ultimately, the path from innovation to standard of care depends on deliberate execution across clinical, commercial, and operational domains. Stakeholders who act proactively to align these elements will capture the greatest value and contribute meaningfully to improved patient outcomes in neurovascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of flow diversion devices for complex intracranial aneurysm treatment improving long-term occlusion rates
  • 5.2. Advances in biodegradable embolic materials reducing risk of chronic inflammation and aiding vessel remodeling
  • 5.3. Integration of real-time robotic-assisted neurovascular navigation systems enhancing procedural precision and safety
  • 5.4. Development of next-generation thin-walled stents for improved vessel conformability and reduced thrombogenicity
  • 5.5. Implementation of artificial intelligence-driven imaging analytics for optimized endovascular procedure planning
  • 5.6. Rise in demand for microcatheters with improved torque control to navigate tortuous cerebral vasculature effectively
  • 5.7. Expansion of hybrid operating room suites combining CT angiography and fluoroscopy to streamline neurointerventions
  • 5.8. Growth in minimally invasive liquid embolic agents enabling targeted vascular occlusion with lower risk profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Intervention Devices Market, by Product Type

  • 8.1. Embolic Agents
    • 8.1.1. Liquid Embolics
    • 8.1.2. Particulate Embolics
  • 8.2. Flow Diverters
    • 8.2.1. Pipeline Embolization Device
    • 8.2.2. Surpass Flow Diverter
  • 8.3. Microcatheters
    • 8.3.1. Hydrophilic Coated
    • 8.3.2. Polymer Coated
  • 8.4. Neurovascular Coils
    • 8.4.1. Detachable Coils
    • 8.4.2. Pushable Coils
  • 8.5. Stents
    • 8.5.1. Balloon Mounted
    • 8.5.2. Self Expanding
  • 8.6. Thrombectomy Devices
    • 8.6.1. Aspiration Devices
    • 8.6.2. Stent Retriever

9. Neurovascular Intervention Devices Market, by Indication

  • 9.1. Aneurysm
  • 9.2. Arteriovenous Malformation
  • 9.3. Stroke

10. Neurovascular Intervention Devices Market, by End User

  • 10.1. Ambulatory Centers
  • 10.2. Clinics
  • 10.3. Hospitals

11. Neurovascular Intervention Devices Market, by Procedure Type

  • 11.1. Embolization
  • 11.2. Flow Diversion
  • 11.3. Thrombectomy

12. Neurovascular Intervention Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Intervention Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Intervention Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Stryker Corporation
    • 15.3.2. Medtronic plc
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Penumbra, Inc.
    • 15.3.5. Boston Scientific Corporation
    • 15.3.6. Terumo Corporation
    • 15.3.7. Becton, Dickinson and Company
    • 15.3.8. MicroPort Scientific Corporation
    • 15.3.9. MicroVention, Inc.
    • 15.3.10. Kaneka Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROVASCULAR INTERVENTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROVASCULAR INTERVENTION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY